CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

10936	Companies
238806	Keywords
167668	Articles
128366	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 1 year 2 months ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 1 year 2 months ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 1 year 2 months ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
BRIEF

published on 06/06/2025 at 17:50, 1 year 2 months ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
BRIEF

published on 06/04/2025 at 20:26, 1 year 3 months ago

CROSSJECT launches a capital increase of nearly 5 million euros

Investment Pharmaceutical Capital Increase Preferential Subscription Right ZEPIZURE®
PRESS RELEASE

published on 06/04/2025 at 20:21, 1 year 3 months ago

Launch of a capital increase with preferential subscription rights for nearly 5 million euros
CROSSJECT announces capital increase with preferential subscription rights totaling nearly 5 million euros. Existing shareholders and Vatel Capital commit to subscribe 76.4% of the amount. Subscription price set at 1.40 euros. Subscription period from June 12 to June 20, 2025

Capital Increase Subscription Period Preferential Subscription Rights Crossject Vatel Capital
BRIEF

published on 06/03/2025 at 07:35, 1 year 3 months ago

Maxim Group Recommends CROSSJECT with €4.00 Target Price

Buy Recommendation Crossject ZEPIZURE® Needle-free Auto-injector Maxim Group
PRESS RELEASE

published on 06/03/2025 at 07:30, 1 year 3 months ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
Maxim Group initiates coverage of CROSSJECT with BUY recommendation and €4.00 target price. CROSSJECT, a specialty pharma company, looks forward to positive developments with FDA and pipeline

FDA Buy Recommendation Specialty Pharma Crossject Maxim Group
BRIEF

published on 05/27/2025 at 07:35, 1 year 3 months ago

CROSSJECT optimizes its production with the ZENEO® Nest

CDMO Funding Production Crossject ZENEO® Nest
BRIEF

published on 05/20/2025 at 07:35, 1 year 3 months ago

CROSSJECT Plans €5 Million Capital Increase to Boost EUA Approval Activities

Capital Increase Crossject ZEPIZURE® Gemmes Venture EUA Approval

Accesswire

Published on 09/05/2026 at 04:05, 3 hours 24 minutes ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 7 hours 59 minutes ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 8 hours 29 minutes ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 8 hours 59 minutes ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 16 hours 59 minutes ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/04/2026 at 22:10, 9 hours 19 minutes ago

Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 12 hours 9 minutes ago

Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:55, 12 hours 34 minutes ago

Holding(s) in Company
Published on 09/04/2026 at 18:50, 12 hours 39 minutes ago

A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 13 hours 24 minutes ago

Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership

Les Echos

Published on 09/04/2026 at 18:57, 12 hours 32 minutes ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 13 hours 44 minutes ago

Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 13 hours 44 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 15 hours 29 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 15 hours 29 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026

View all LES ECHOS COMFI WIRE